Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study
- 29 August 2024
- journal article
- research article
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (5) , 3957-3973
Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a disease characterized by pulmonary interstitial fibrosis and collagen proliferation, currently lacking effective therapeutic options. The combined use of Celastrol and Ligustrazine has been proved to synergistically improve the pathological processes of inflammation and fibrosis. In earlier studies, we designed and synthesized a Celastrol-Ligustrazine compound CL-001, though its role in IPF remains unclear. Here, the effects and mechanisms of CL-001 in bleomycin (BLM)-induced IPF were investigated. In vivo, CL-001 significantly improved lung function, reduced pulmonary inflammation, and decreased collagen deposition, thereby preventing the progression of IPF. In vitro, CL-001 concurrently inhibited both Smad-dependent and Smad-independent pathways, thereby suppressing TGF-β1-induced epithelial-mesenchymal transition (EMT) and epithelial cell migration. This inhibitory effect was superior to that of Celastrol or Ligustrazine administered alone. Additionally, CL-001 significantly increased the level of apoptosis and promoted the expression of apoptosis-related proteins (Caspase-8 and PARP), ultimately leading to widespread apoptosis in activated lung epithelial cells. In summary, CL-001 exhibits excellent anti-IPF effects both in vitro and in vivo, suggesting its potential as a novel candidate drug for IPF, warranting further development.Keywords
Funding Information
- National Natural Science Foundation of China (81971483)
This publication has 49 references indexed in Scilit:
- Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALIJournal of Ethnopharmacology, 2022
- Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyteBiomedicine & Pharmacotherapy, 2022
- Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1Acta Pharmaceutica Sinica B, 2021
- Dehydrocostus lactone inhibits BLM-induced pulmonary fibrosis and inflammation in mice via the JNK and p38 MAPK-mediated NF-κB signaling pathwaysInternational Immunopharmacology, 2021
- Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatoninLife Sciences, 2018
- Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and AutophagyMolecular Cell, 2017
- Hydroxysafflor Yellow A Attenuates Bleomycin‐induced Pulmonary Fibrosis in MicePhytotherapy Research, 2016
- Effective myofibroblast dedifferentiation by concomitant inhibition of TGF-β signaling and perturbation of MAPK signalingEuropean Journal of Cell Biology, 2013
- Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseasesBiochemical Pharmacology, 2012
- Structural Basis of Heteromeric Smad Protein Assembly in TGF-β SignalingMolecular Cell, 2004